Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1020 + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SHR-1020 combined with albumin-bound paclitaxel is an investigational combination therapy being studied for the second-line treatment of advanced pancreatic cancer. This combination works through multiple mechanisms including blocking tumor mitosis, inhibiting tumor angiogenesis, and inhibiting interstitial fibrosis to achieve anti-tumor effects. Albumin-bound paclitaxel (also known as nab-paclitaxel) is a solvent-free formulation of paclitaxel that uses albumin nanoparticles to deliver the active ingredient more effectively to tumor cells.
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SHR-1020 + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1020 + albumin-bound paclitaxel.